Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

智通财经APP获悉，专注于肥胖治疗的生物技术公司Metsera周一公布了其首次公开募股（IPO）的相关条款。这家总部位于纽约的公司计划通过发行1720万 ...

US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is ...

临床阶段的生物技术公司Metsera(股票代码：“MTSR”）日前更新招股书，准备本周五在美国纳斯达克上市。 Metsera发行区间为15美元到17美元，发行1718.75 ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.